Altamira Therapeutics Ltd. (CYTOF) Operating cash flow 2022–2024
Altamira Therapeutics Ltd. (CYTOF) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$6.1MFY2024 · since FY2022: -$9.1M → -$6.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$6.1M | +52.3% |
| FY2023 | -$12.8M | -40.9% |
| FY2022 | -$9.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CYTOF financial trends
CYTOF RevenueCYTOF Net incomeCYTOF Net marginCYTOF Gross profitCYTOF Gross marginCYTOF Operating incomeCYTOF Operating marginCYTOF Free cash flowCYTOF Capital expendituresCYTOF Return on equityCYTOF Stock buybacksCYTOF Dividends paidCYTOF Total assetsCYTOF Total liabilitiesCYTOF Shareholders’ equityCYTOF overview →